Ad5-nCoV

CanSino beats Moderna again, this time to peer-reviewed, published Covid-19 vaccine data

The Tianjin, China-based company, which was the first to move a vaccine into Phase II development, also became the first to published peer-reviewed data, from its Phase I study. Moderna released preliminary data this week, but it was seen as too early for interpreting its vaccine's efficacy.

By Alaric DeArment

BioPharma

CanSino Biologics may start clinical development of Covid-19 vaccine in Canada

The Tianjin, China-based company and a Canadian federal research institution plan to advance bioprocessing and clinical development of Ad5-nCoV in Canada. CanSinoBIO is currently running a Phase II clinical trial in China.

By Alaric DeArment

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.